SCA


Healthy Q2 results; now all eyes on forest valuation review

28/08/19 -"After an extraordinary H2 18, performance normalisation has been picking up momentum in 2019. Yet, despite softening markets, SCA managed to attain an impressive Q2 performance. Continuation of the ..."

Pages
52
Language
English
Published on
28/08/19
You may also be interested by these reports :
08/11/19
Ever since mighty Essity (ADD, Sweden) demerged from SCA (ADD, Sweden) in June 2017, it seemed that the former – driven by sacrosanct global ‘health ...

01/11/19
Even though market conditions have become tougher, UPM managed to limit its Q3 business impact via effective cost savings. Interestingly, management ...

31/10/19
As expected, pricing normalisation is gathering momentum across the respective divisions. Yet, SCA’s Q3 profitability exceeded consensus estimates ...

30/10/19
Q3 performance came under (more-than-expected) pressure due to price and volume headwinds across most divisions. The dismal Q4 performance outlook ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO